In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sagent Pharmaceuticals Inc.

www.sagentpharma.com

Latest From Sagent Pharmaceuticals Inc.

International Expansion Stays On Nichi-Iko’s Agenda As Sagent Struggles

Japan’s Nichi-Iko is looking to grow its overseas sales by around a fifth each year, even as its North American injectables affiliate Sagent struggles to move forward and to make a profit.

 

Business Strategies Japan

People Round-Up: Bhadauria Named As Amneal CSO

Amneal gets a new CSO, Acino restructures its board under a new chair, the AAM adds an assistant general counsel and the British Biosimilars Association names a vice-chair, as well as other people movements from around the generics, biosimilars and value-added medicines industries.

Appointments Strategy

Scrip 100 Analysis: Sales Up, Profits Down – But Is It Real?

Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?

Scrip 100 Sales & Earnings

Aprogen/Nichi-Iko's Remicade Biosimilar Clears Japan’s Approval Review

South Korea's Aprogen, which has teamed up with Japan's Nichi-Iko, is set to receive an official regulatory approval for its biosimilar infliximab in Japan and launch the product possibly this year, becoming the second Remicade biosimilar to be marketed in the country after Celltrion's Remsima.

Biosimilars Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sagent Pharmaceuticals Inc.
  • Senior Management
  • Allan Oberman, CEO
    Jonathon M Singer, EVP, CFO
    Frank Harmon, EVP, Global Ops
    Sean Brynjelsen, EVP, Bus. Dev.
    Jeffrey Greve, Controller
  • Contact Info
  • Sagent Pharmaceuticals Inc.
    Phone: (847) 908-1600
    1901 N. Roselle Rd.
    Schaumburg, IL 60195
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register